PanGenomic Health (XCNQ:NARA) Debt-to-Equity : -0.34 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is PanGenomic Health Debt-to-Equity?

PanGenomic Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$0.63 Mil. PanGenomic Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$0.00 Mil. PanGenomic Health's Total Stockholders Equity for the quarter that ended in Sep. 2023 was C$-1.83 Mil. PanGenomic Health's debt to equity for the quarter that ended in Sep. 2023 was -0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PanGenomic Health's Debt-to-Equity or its related term are showing as below:

XCNQ:NARA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.47 Med: -0.34 Max: -0.26
Current: -0.34

During the past 2 years, the highest Debt-to-Equity Ratio of PanGenomic Health was -0.26. The lowest was -0.47. And the median was -0.34.

XCNQ:NARA's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.48 vs XCNQ:NARA: -0.34

PanGenomic Health Debt-to-Equity Historical Data

The historical data trend for PanGenomic Health's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PanGenomic Health Debt-to-Equity Chart

PanGenomic Health Annual Data

Trend

Dec21

Dec22

Debt-to-Equity

-0.47

PanGenomic Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial					-	-0.47	-0.26	-0.35	-0.34

Competitive Comparison of PanGenomic Health's Debt-to-Equity

For the Health Information Services subindustry, PanGenomic Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PanGenomic Health's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PanGenomic Health's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PanGenomic Health's Debt-to-Equity falls into.

PanGenomic Health Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PanGenomic Health's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.102	+	0)	/	-0.215
	=	-0.47

PanGenomic Health's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.627	+	0)	/	-1.829
	=	-0.34

PanGenomic Health (XCNQ:NARA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PanGenomic Health Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PanGenomic Health's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PanGenomic Health (XCNQ:NARA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PanGenomic Health Inc (XCNQ:NARA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NARA:UK LL30:Germany

Address

3800 Wesbrook Mall, Suite 102, Vancouver, BC, CAN, V6S 2L9

Website

https://www.pangenomic.com

PanGenomic Health Inc is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provides consumers with a knowledge base tailored to an individual's user profile, developed by tracking a user's treatment regimen and their specific genomic, proteomics, and microbiome data. The Company's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

Executives

Kaidong Zhang

Senior Officer

PanGenomic Health (XCNQ:NARA) Headlines

No Headlines